| Literature DB >> 29629102 |
Brandon A Vara1, Xingpin Li1, Simon Berritt1, Christopher R Walters1, E James Petersson1, Gary A Molander1.
Abstract
Site-specific functionalization of unprotected nativeEntities:
Year: 2017 PMID: 29629102 PMCID: PMC5868321 DOI: 10.1039/c7sc04292b
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Proposed Ni/photoredox catalytic cycle and thioarylation reaction scheme. (A) Catalytic cycle is initiated by photon absorption, generating excited state Ru photocatalyst, followed by oxidation of the HAT reagent via SET. Rapid H-atom abstraction from the sulfhydryl group generates a thiyl radical, which adds to Ni(0). This is followed by Ni(i) oxidative addition23 with the requisite aryl bromide. Reductive elimination from Ni(iii) affords the desired thioarylated biomolecule, and the dual catalytic cycles are closed by a final SET. (B) Ni/photoredox thioarylation reaction with GSH (1) and 2 affords the arylated peptide. Select experiments are outlined that deviate from the general conditions. Additional experiments and the structure of 4CzlPN can be found in the ESI.†
Chart 1Ni/Photoredox thioarylation reaction and scope of various thiol and arene small molecules. iBu[Si–] = diisopropylammonium bis(catechol)isobutylsilicate. DMF = N,N-dimethylformamide. Reactions conducted with 0.1 mmol thiol and ArBr, unless otherwise noted; isolated yields are reported (TFA salt omitted for clarity, see ESI† for additional details). 0.12 mmol GSH employed. §2 equiv. ArBr was employed. †The adduct was filtered following precipitation from the aqueous solution.
Fig. 2Rapid exploration of Merck aryl halide informer plate via HTE and tolerability studies of biological additives under optimized conditions. (A) Merck halides run with 4 diverse thiols; reported numbers in cells present product area%/internal std area% (normalized). (B) Structures of successful Merck halides (X1–X15) as explored in A. (C) Biological additives (1 equiv., box a; 0.5 equiv., box b) were screened under optimized conditions; yield determined vs. internal standard (average of 2 runs).
Fig. 3Application of thioarylation reaction conditions to native and diverse biological substrates. (A) Optimized “dilute conditions” with GSH at 10 mM for enabling small-scale peptide thioarylations. Employing 20 equiv. of aryl bromide, 2 was found to increase relative reaction rate, as compared to 5 mM reactions vs. time. (B) Peptide 9 was subjected to optimized conditions at 10 mM for 90 min under blue LED irradiation. HPLC chromatogram depicts reaction progression and formation of product (see ESI† for reaction details). (C) Thioarylation of coenzyme A (11, 3Li salt) with three diverse aryl bromides (4 equiv. silicate 4 employed) afforded the conjugated products under the developed conditions in all cases.
Fig. 4(A) Demonstration of reaction scalability for the Ni/photoredox thioarylation of peptides (see ESI† for details); isolated yields reported. (B) Dilute conditions employed: 5 mol% Ni 5, 2 mol% Ru 6, and 1.5 equiv. silicate 4. HPLC yields reported via product/internal standard ratios.